Form 4: LMAT Director Roberts Receives Equity Awards

Lemaitre Vascular's President and Director, David B. Roberts, was granted 1,694 restricted stock units and 10,400 stock options.

Summary

• David B. Roberts, President and Director of Lemaitre Vascular Inc. (LMAT), received equity awards on December 10, 2025.
• The awards include 1,694 shares of common stock as restricted stock units (RSUs) at a price of $0.
• The RSUs vest 25% on December 1, 2026, with the remainder vesting in equal annual installments over the subsequent three years.
• The awards also include 10,400 stock options with an exercise price of $83.66 per share.
• These stock options vest over a four-year period, with 25% vesting on the first anniversary of December 1, 2025, and the balance vesting in equal annual installments over the remaining three years.
• The stock options have an expiration date of December 10, 2032.
• Following these transactions, Mr. Roberts beneficially owns 23,091 shares of common stock and 10,400 stock options directly.

Sentiment

Score: 7

Explanation: The filing reports a routine equity compensation grant to a key executive, which is generally positive for aligning management incentives with shareholder interests. It does not contain any negative news or unexpected events.

Positives

• Grant of restricted stock units (RSUs) and stock options to a key executive aligns management's interests with shareholder value.
• The awards incentivize long-term performance and retention of President and Director David B. Roberts.

Future Outlook

The restricted stock units and stock options granted to David B. Roberts are subject to time-based vesting schedules, extending through December 1, 2029, for RSUs and December 1, 2028, for stock options (assuming 4-year vesting from 12/1/2025). This indicates a long-term incentive structure for a key executive.

Industry Context

This filing reflects standard executive compensation practices within the medical device industry, where equity awards like RSUs and stock options are commonly used to attract, retain, and incentivize key management personnel by aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options for executive compensation is a common practice across the medical device industry, similar to companies like Medtronic (MDT) or Boston Scientific (BSX), which frequently utilize such equity-based incentives to align executive interests with shareholder value.
• The four-year vesting schedule for both awards is standard for long-term incentive plans, comparable to typical vesting periods seen in executive compensation packages at peer companies.
• The grant of awards at a $0 price for RSUs is typical, representing a direct share grant, while the stock option exercise price of $83.66 likely reflects the market price on the grant date, a common practice to ensure options are "at-the-money" upon issuance.

Stakeholder Impact

• Shareholders: The equity awards align the interests of President and Director David B. Roberts with long-term shareholder value, potentially leading to more focused efforts on company performance.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive programs.

Next Steps

• 25% of the restricted stock unit award will vest on December 1, 2026.
• The remaining balance of the restricted stock units will vest in equal annual installments over the three years following December 1, 2026.
• 25% of the stock options will vest on the first anniversary of December 1, 2025 (i.e., December 1, 2026).
• The remaining balance of the stock options will vest in equal annual installments over the three years following December 1, 2026.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a key executive, which is a standard practice to align management incentives with shareholder interests. It does not provide new financial performance data, strategic shifts, or material events that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate, maintaining the current stance based on broader company fundamentals rather than this specific insider transaction.

Keywords

Lemaitre Vascular, LMAT, David B. Roberts, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Award, Executive Compensation, Beneficial Ownership